1.3.1.22: 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+) This is an abbreviated version! For detailed information about 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+), go to the full flat file .
Reaction
a 3-oxo-5alpha-steroid +
NADP+ =
a 3-oxo-DELTA4-steroid +
NADPH +
H+
Synonyms 3-oxosteroid 5alpha-reductase, 3-oxosteroid DELTA4-dehydrogenase, 4-ene-3-oxosteroid 5alpha-reductase, 4-ene-5alpha-reductase, 5 alpha-R2, 5 alpha-reductase type 2, 5-alpha reductase I, 5-alpha reductase II, 5-alpha-reductase type 1, 5-alpha-reductase type 2, 5a-reductase type 1, 5a-reductase type 2, 5A2, 5alpha-R1, 5alpha-R2, 5alpha-reductase 1, 5alpha-reductase II, 5alpha-reductase type 1, 5alpha-reductase type 2, 5alpha-reductase type II, 5alpha-SR2, 5alphaR, 5alphaR type 2, 5alphaR1, 5alphaR2, AtDET2, brainneurosteroidogenic 5x02-reductase 1, cholest-4-en-3-one 5alpha-reductase, cortisone alpha-reductase, cortisone DELTA 4-5alphareductase, DCC71_03205, DELTA4-3-ketosteroid 5alpha-oxidoreductase, DELTA4-3-ketosteroid reductase (5alpha), DELTA4-3-oxosteroid-5 alpha-reductase, DELTA4-5alpha-reductase, DELTA4-steroid 5alpha-reductase (progesterone), EC 1.3.1.30, EC 1.3.1.4, LeDET2, microsomal steroid reductase (5alpha), More, NADPH:DELTA4-3-oxosteroid-5alpha-oxidoreductase, neurosteroidogenic 5alpha-reductase 1, progesterone 5alpha-reductase, reduced nicotinamide adenine dinucleotide phosphate:DELTA4-3-ketosteroid 5alpha-oxidoreductase, reductase, cholestenone 5alpha-, reductase, cortisone DELTA: 4-5alpha-, reductase, progesterone 5alpha-, S5alphaR, SRD5A1, SRD5A2, SRDA1, SRDA2, SRDA3, steroid 5-alpha reductase, steroid 5-alpha-reductase, steroid 5alpha reductase type 2, steroid 5alpha-hydrogenase, steroid 5alpha-reductase, steroid 5alpha-reductase type II, testosterone 5alpha-reductase, testosterone delta4-5alpha-reductase, testosterone delta4-hydrogenase, type 1 5alpha-reductase, type 1 5alphaR, type 1 SR, type 1 steroid 5alpha reductase, type 1 steroid 5alpha-reductase, type 2 5alpha-reductase, type 2 5alphaR, type 2 SR, type 2 steroid 5alpha reductase, type 2 steroid 5alpha-reductase, type II 5alpha-reductase, type-1 5alpha-reductase, type-2 5alpha-reductase
ECTree
Engineering
Engineering on EC 1.3.1.22 - 3-oxo-5alpha-steroid 4-dehydrogenase (NADP+)
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
K204E
-
det2-1 mutant, substitution of lysine for Glu-204 totally inactivates the steroid 5alpha-reductase activity, residual activity for campestenone and progesterone
A207D
-
the mutation is associated with 5alpha-reductase type 2 deficiency
A248V
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
A51T
-
constitutional variant, reduction of the apparent Ki for both finasteride and dutasteride
C133G
-
the mutation is associated with 5alpha-reductase type 2 deficiency
C5R
-
constitutional variant, reduction of the apparent Ki for both finasteride and dutasteride
F118L
-
somatic variant, no significant change of the apparent Ki for both finasteride and dutasteride
F194L
-
constitutional variant, time-independent inhibition, displays lower apparent Ki for finasteride than dutasteride
F234L
-
constitutional variant, reduction of the apparent Ki for finasteride but not for dutasteride
G183D
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
G183S
-
mutant of 5alpha-reductase isozyme type-2
G191E
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
G34R
-
mutant of 5alpha-reductase isozyme type-2
G34W
-
the mutation is associated with 5alpha-reductase type 2 deficiency
H231R
-
mutant of 5alpha-reductase isozyme type-2
H264Q
-
mutant of 5alpha-reductase isozyme type-2
L221P
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
L226P
-
somatic variant, reduction of the apparent Ki for finasteride but not for dutasteride
L55Q
the naturally occuring homozygote point mutation causes SRD5A2 deficiency and leads to leading to an impaired conversion of testosterone to 5alpha-dihydrotestosterone, and thus to predominantly female phenotype at 3 days of age with ambiguous external genitalia: testes palpable in the extended labia resembling a scrotum bipartitum, micropenis with hypospadias and lack of an introitus vaginae but a perineal dimple in accordance with steroid 5alpha-reductase deficiency type III
N193S
-
mutant of 5alpha-reductase isozyme type-2
P181L
-
mutant of 5alpha-reductase isozyme type-2
P30L
-
constitutional variant, more than 100fold lower apparent Ki for dutasteride than for finasteride
P48R
-
constitutional variant, displays lower apparent Ki for finasteride than dutasteride in the 10 min reaction
R145W
-
mutant of 5alpha-reductase isozyme type-2
R171S
-
mutant of 5alpha-reductase isozyme type-2
R227Q
-
constitutional variant, reduction of the apparent Ki for both finasteride and dutasteride
R246W
-
mutant of 5alpha-reductase isozyme type-2
T187M
-
constitutional variant, reduction of the apparent Ki for both finasteride and dutasteride
V189A
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
V3I
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
V63M
-
somatic variant, reduction of the apparent Ki for both finasteride and dutasteride
W53X
-
the mutation is associated with 5alpha-reductase type 2 deficiency
Y235F
-
the mutation is associated with 5alpha-reductase type 2 deficiency
additional information
Arabidopsis wild type and enzyme mutant strains carrying the enzyme gene controlled by cauliflower mosaic virus 35S promotor differed from wild type plants by accelerated stem growth, flower and seed development and a reducution in size and number of rosette leaves
A49T
-
constitutional and somatic variant, time-independent inhibition, more than 100fold lower apparent Ki for dutasteride than for finasteride
A49T
-
the mutation is associated with 5alpha-reductase type 2 deficiency
G196S
-
mutant of 5alpha-reductase isozyme type-2
G196S
-
the mutation is associated with 5alpha-reductase type 2 deficiency
V89L
-
constitutional variant, reduction of the apparent Ki for both finasteride and dutasteride
V89L
-
the mutant of low 5-alpha-reductase type 2 activity is associated with an increased risk of aggressive prostate cancer
V89L
a significant sex-dependent effect of genotype for the V89L variant in male but not female subjects on symptoms of post-traumatic stress disorder